Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease ; volume:68 ; number:7 ; day:17 ; month:3 ; year:2023 ; pages:3119-3128 ; date:7.2023
Digestive diseases and sciences ; 68, Heft 7 (17.3.2023), 3119-3128, 7.2023
- Creator
-
Eriksson, Carl
Söderling, Jonas
Karlqvist, Sara
Bröms, Gabriella
Everhov, Åsa H.
Bergemalm, Daniel
Ludvigsson, Jonas F.
Olén, Ola
Halfvarson, Jonas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-023-07897-2
- URN
-
urn:nbn:de:101:1-2023092711121255214559
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Eriksson, Carl
- Söderling, Jonas
- Karlqvist, Sara
- Bröms, Gabriella
- Everhov, Åsa H.
- Bergemalm, Daniel
- Ludvigsson, Jonas F.
- Olén, Ola
- Halfvarson, Jonas
- SpringerLink (Online service)
Other Objects (12)
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar